Filing Flows › Comparisons › VERA vs IDYA
Vera Therapeutics vs Ideaya Biosciences: VERA and IDYA compared
Vera Therapeutics is the larger company: $10.3M of revenue in its latest quarter (Q3 2026) against $10.2M for Ideaya Biosciences (Q3 2026).
Where the money goes: VERA and IDYA
Vera Therapeutics (VERA) · Q3 2026
Vera Therapeutics, Q3 2026: revenue $10.3M, operating margin -931.2%, net loss $93.7M, operating cash flow −$99.2M. The chart follows the revenue to costs, profit and cash.
Ideaya Biosciences (IDYA) · Q3 2026
Ideaya Biosciences, Q3 2026: revenue $10.2M (-95% year over year), net loss $126M, operating cash flow −$93.5M. The chart follows the revenue to costs, profit and cash.
| Vera Therapeutics (VERA) | Ideaya Biosciences (IDYA) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $10.3M | $10.2M |
| Revenue growth, Y/Y | — | -95% |
| Operating margin | -931.2% | n/m |
| Net earnings | −$93.7M | −$126M |
| Net margin | -911.9% | — |
| Operating cash flow | −$99.2M | −$93.5M |
| Market value | — | $3.7B |
| Analysts’ mean target | — | $51.38 |
Questions
Which is bigger, Vera Therapeutics or Ideaya Biosciences?
Vera Therapeutics is the larger company: $10.3M of revenue in its latest quarter (Q3 2026) against $10.2M for Ideaya Biosciences (Q3 2026).
More: Vera Therapeutics earnings · how Vera Therapeutics makes money · Ideaya Biosciences earnings · how Ideaya Biosciences makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Nov 3, 2026). Fiscal quarters can end on different dates. Not investment advice.